Match!

Counting the true cost and value of medicines.

Published on Feb 1, 2003in Oncologist5.252
· DOI :10.1634/theoncologist.8-1-2
Robert A. Ingram1
Estimated H-index: 1
Abstract
  • References (5)
  • Citations (3)
📖 Papers frequently viewed together
3 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References5
Newest
#1James P. BoyleH-Index: 15
#2Amanda HoneycuttH-Index: 15
Last. Theodore J. ThompsonH-Index: 42
view all 7 authors...
OBJECTIVE —To project the number of people with diagnosed diabetes in the U.S. through 2050, accounting for changing demography and diabetes prevalence rates. RESEARCH DESIGN AND METHODS —We combined age-, sex-, and race-specific diagnosed diabetes prevalence rates—predicted from 1980–1998 trends in prevalence data from the National Health Interview Survey—with Bureau of Census population demographic projections. Sensitivity analyses were performed by varying both prevalence rate and population ...
854 CitationsSource
Dramatic declines in the incidence of AIDS and the number of deaths from this disease began in the United States in 1996, in association with the widespread use of potent combinations of antiretroviral drugs. Subsequently, the rates of decline have slowed and begun to level. As of June 2000, more than 300,000 people were estimated to be living with AIDS. Each year, there are about 40,000 new infections with the human immunodeficiency virus (HIV) and 16,000 deaths from AIDS. About one third of th...
20 CitationsSource
#1Susan C. Fagan (HFHS: Henry Ford Health System)H-Index: 6
#2Lewis B. Morgenstern (University of Texas at Austin)H-Index: 60
Last. M. D. Walker (NIH: National Institutes of Health)H-Index: 1
view all 12 authors...
Tissue plasminogen activator (tPA) has been shown to improve 3-month outcome in stroke patients treated within 3 hours of symptom onset. The costs associated with this new treatment will be a factor in determining the extent of its utilization. Data from the NINDS rt-PA Stroke Trial and the medical literature were used to estimate the health and economic outcomes associated with using tPA in acute stroke patients. A Markov model was developed to estimate the costs per 1,000 patients eligible for...
345 CitationsSource
#1Henry G. Grabowski (Duke University)H-Index: 39
#2John M Vernon (Duke University)H-Index: 17
Abstract This study finds that the mean IRR for 1980–1984 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes in the baseline assumptions. Our work is also compared with a 1993 study by the OTA. Despite some important differences in assumptions, both studies imply that returns for the average NCE are within one percentage point of the industry's cost of capital. This is much...
173 CitationsSource
#1William P. Peters (Duke University)H-Index: 38
#2Gary L. Rosner (Duke University)H-Index: 44
Last. Joanne Kurtzberg (Duke University)H-Index: 80
view all 7 authors...
Two hematopoietic colony-stimulating factors, granulocyte colony- stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF), have been shown to accelerate leukocyte and neutrophil recovery after high-dose chemotherapy and autologous bone marrow (BM) support. Despite their use, a prolonged period of absolute leukopenia persists during which infections and other complications of transplantation occur. We collected large numbers of peripheral blood (PB) progenitors after CSF administration...
246 CitationsSource
Cited By3
Newest
Resumen En la validacion de la quimioterapia oral, el farmaceutico debe comprobar la idoneidad de la prescripcion, asi como la correccion de su contenido, aplicando los mismos estandares de seguridad para los citostaticos parenterales. Cada vez hay mas canceres que tienen disponibles tratamientos por via oral, mejorando la satisfaccion del paciente, ya que pueden tomarse en sus domicilios sin necesidad de visitar el hospital. A medida que se incrementen los tratamientos citostaticos por via oral...
Source
#1Arsia Amir-Aslani (University of Paris)H-Index: 2
#2Syoum Negassi (University of Paris)H-Index: 4
Abstract The demand for innovative and cost-effective products has had considerable impact on the Research and Development (R&D) portfolio of pharmaceutical companies. With the advent of the new enabling technologies, the biotechnology revolution has created a need for a new and more appropriate paradigm for drug development. The progress in the biological understanding of disease processes and related technological developments have been a major step forward for drug discovery. However, the gre...
41 CitationsSource